BioRestorative Therapies

BioRestorative Therapies FCF per Share

The Free Cash Flow per Share of BioRestorative Therapies (BRTX) as of Nov 3, 2026 is -24.57 USD. In the previous year, Free Cash Flow per Share was -24.09 USD — a change of 1.98% (lower).

FCF per Share

-24.57USD

YoY

1.98%

Last updated:

Free Cash Flow per Share of BioRestorative Therapies is 2025 -24.57 USD. Free Cash Flow per Share of BioRestorative Therapies was 2024 -24.09 USD. It decreases by 1.98% lower compared to the previous year.

The BioRestorative Therapies FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-51,174.98 USD
Jan 1, 2019
-43.60 USD
Jan 1, 2020
-5.02 USD
Jan 1, 2021
-19.09 USD
Jan 1, 2022
-34.64 USD
Jan 1, 2023
-1.40 USD
Jan 1, 2024
-24.09 USD
Jan 1, 2025
-24.57 USD
The BioRestorative Therapies FCF per Share history
YEARFCF per ShareYoY
-24.57USD+1.98%
-24.09USD+1,617.98%
-1.40USD-95.95%
-34.64USD+81.43%
-19.09USD+280.66%
-5.02USD-88.50%
-43.60USD-99.91%
-51,174.98USD+2,155.32%
-2,269.08USD-95.63%
-51,914.39USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

Free Cash Flow per Share of BioRestorative Therapies is -24.57 USD in 2025.

Free Cash Flow per Share of BioRestorative Therapies changed from -24.09 USD to -24.57 USD, representing a 1.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioRestorative Therapies

All Key Metrics — BioRestorative Therapies